Connect with us

Technology

5N Plus Reports 2023 Fourth Quarter and Annual Financial Results

Published

on

Record reported Adjusted EBITDA1 of $38.3 million in FY 2023Adjusted gross margin1 of 29.0% for FY 2023Net earnings of $2.3 million in Q4 2023 and $15.4 million in FY 2023Net debt to EBITDA ratio1 of 1.69x as at December 31, 2023

MONTRÉAL, Feb. 27, 2024 /CNW/ – 5N Plus Inc. (TSX: VNP) (“5N+” or “the Company”), a leading global producer of specialty semiconductors and performance materials, today announced its financial results for the fourth quarter of fiscal 2023 (“Q4 2023”) and fiscal year (“FY 2023”) ended December 31, 2023. All amounts in this press release are expressed in U.S. dollars unless otherwise stated.

“For FY 2023, we delivered record reported Adjusted EBITDA and significant margin expansion, while sustaining a strong backlog1. Our performance across these key performance indicators is proof that our strategy – focused on commercial excellence, value-added products and long-term partnerships – is delivering tangible results, while also enabling us to provide increased visibility on our near-term growth path.

“Records are made to be broken and it is our objective to do just that in the coming years. We are confident in our approach and, as reflected in our guidance for 2024 and 2025, we expect to be able to keep levelling up our performance. We will continue to leverage our unique position as a trusted partner for ultra-high purity specialty semiconductors and performance materials, and to capitalize on growing demand in critical end markets like terrestrial renewable energy and space solar power,” said Gervais Jacques, President and CEO of 5N+.

Q4 2023 Highlights

Revenue in Q4 2023 reached $65.1 million, compared to $61.0 million for the same period last year. The 7% increase is primarily attributable to higher demand in the Specialty Semiconductors segment, offset by lower revenue in the Performance Materials segment following the strategic exit from the manufacturing of low-margin extractive and catalytic products in 2022.Net earnings in Q4 2023 were $2.3 million compared to a net loss of $8.1 million in Q4 2022. Net earnings in FY 2023 were $15.4 million compared to a net loss of $23.0 million in FY 2022.Adjusted EBITDA in Q4 2023 was $9.0 million, a 35% increase over the $6.7 million for the same period last year. Adjusted EBITDA was $38.3 million in FY 2023, a 28% increase compared to $30.0 million in FY 2022.Adjusted gross margin in FY 2023 was 29.0%, compared to 23.7% in FY 2022.On December 31, 2023, the backlog represented 292 days of annualized revenue, 8 days higher than the previous quarter and 39 days higher than the same period last year, primarily due to increasing demand in both terrestrial renewable energy and space solar power.Net debt1 was $73.8 million as at December 31, 2023, compared to $78.3 million as at December 31, 2022.

_____________________________

1  These measures are not recognized measures under IFRS and do not have standardized meanings prescribed by IFRS and therefore may not be comparable to similar measures presented by other companies. See Non-IFRS Measures for more information.

Outlook

In Specialty Semiconductors, 5N+ continues to benefit from its unique position as the leading global supplier of ultra-high purity semiconductor compounds outside China, with extensive expertise and a favourable global footprint resulting in a reliable supply chain. The Company’s products can be found in a wide range of technologies used in critical applications and everyday products.

Growing demand remains the rule in Specialty Semiconductors end markets, particularly in terrestrial renewable energy and space solar power. This positions 5N+ well to capitalize on future opportunities in these high-growth sectors, as well as other markets, including defense, security and medical imaging, and through its long-term partnerships with key customers.

Management expects growth in the Performance Materials segment to be primarily derived from health and pharmaceutical products, which provide high profitability and predictable cashflows. Additional long-term opportunities are expected to stem from product expansion or development initiatives, including through partnerships.

Furthermore, management continues to seek opportunities to increase operational efficiency, while exploring potential acquisitions and partnerships to enhance its own organic growth and leadership market position.

With the visibility afforded to management as a result of the solid execution of its business strategy over the last few years, its improved product mix and strong backlog, management is committed to sustaining its trajectory with respect to Adjusted EBITDA growth and margin improvements. To that end, management is maintaining its previously disclosed projected Adjusted EBITDA range for FY 2024 to be between $45 million and $50 million and expects Adjusted EBITDA for FY 2025 to be between $50 million and $55 million, supported by organic growth.

To meet these objectives, 5N+ will continue to execute on its value-added focused strategy and commercial excellence program, leveraging its competitive advantages stemming from its unique positioning both from a geographic and expertise standpoint. As a trusted partner in the development and manufacturing of critical specialty semiconductors and performance materials with a customer-centric mentality, the Company will also continue methodically investing in its production capacity to serve high-growth markets and strategic global customers.

Conference Call

5N+ will host a conference call on Wednesday, February 28, 2024, at 8:00 am Eastern Time to discuss fourth quarter and annual results for fiscal 2023. All interested parties are invited to participate in the live broadcast on the Company’s website at www.5nplus.com.

To participate in the conference call:

Toronto area: 416-764-8659Toll‐Free: 1-888-664-6392Enter access code: 94847778

A replay of the conference call will be available two hours after the event and until March 6, 2024. To access the recording, please dial 1-888-390-0541 and enter access code 847778.

About 5N Plus Inc.

5N+ is a leading global producer of specialty semiconductors and performance materials. The Company’s ultra‐pure materials often form the core element of its customers’ products. These customers rely on 5N+’s products to enable performance and sustainability in their own products. 5N+ deploys a range of proprietary and proven technologies to develop and manufacture its products. The Company’s products enable various applications in several key industries, including renewable energy, security, space, pharmaceutical, medical imaging and industrial. Headquartered in Montréal, Quebec, 5N+ operates R&D, manufacturing and commercial centers in strategically located facilities around the world including Europe, North America and Asia.

Forward‐Looking Statements

Certain statements in this press release may be forward‐looking within the meaning of applicable securities laws. Such forward‐looking statements are based on a number of estimates and assumptions that the Company believes are reasonable when made, including that 5N+ will be able to retain and hire key personnel and maintain relationships with customers, suppliers and other business partners, that 5N+ will continue to operate its business in the normal course, that 5N+ will be able to implement its growth strategy, that 5N+ will be able to successfully and timely complete the realization of its backlog, that 5N+ will not suffer any supply chain challenges or any material disruption in the supply of raw materials on competitive terms, that 5N+ will be able to generate new sales, produce, deliver, and sell its expected product volumes at the expected prices and control its costs, as well as other factors believed to be appropriate and reasonable in the circumstances. However, there can be no assurance that such estimates and assumptions will prove to be correct. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict and may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward‐looking statements. A description of the risks affecting the Company’s business and activities appears under the heading “Risk and Uncertainties” of the Company’s 2023 MD&A dated February 27, 2024, available on www.sedarplus.ca.

Forward‐looking statements can generally be identified by the use of terms such as “may”, “should”, “would”, “believe”, “expect”, the negative of these terms, variations of them or any similar terms. No assurance can be given that any events anticipated by the forward‐looking statements in this press release will transpire or occur, or if any of them do so, what benefits that 5N+ will derive therefrom. In particular, no assurance can be given as to the future financial performance of 5N+. The forward‐looking statements contained in this press release is made as of the date hereof and the Company has no obligation to publicly update such forward‐looking information to reflect new information, subsequent or otherwise, unless required by applicable securities laws. The reader is warned against placing undue reliance on these forward‐looking statements.

5N PLUS INC.
CONSOLIDATED STATEMENTS OF EARNINGS (LOSS)
Years ended December 31
(in thousands of United States dollars, except per share information)

2023

2022

$

$

Revenue

242,371

264,223

Cost of sales

184,833

215,715

Selling, general and administrative expenses

29,410

28,565

Other expenses (income), net

756

32,997

214,999

277,277

Operating earnings (loss)

27,372

(13,054)

Financial expenses

Interest on long-term debt

8,262

5,466

Imputed interest and other interest expense (income)

572

(274)

Foreign exchange and derivative (gain) loss

(136)

42

8,698

5,234

Earnings (loss) before income taxes

18,674

(18,288)

Income tax expense (recovery)

Current

6,674

6,865

Deferred

(3,399)

(2,154)

3,275

4,711

Net earnings (loss)

15,399

(22,999)

Basic earnings (loss) per share

0.17

(0.26)

Diluted earnings (loss) per share

0.17

(0.26)

Net earnings (loss) are completely attributable to equity holders of 5N Plus Inc.

5N PLUS INC.
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(in thousands of United States dollars)

December 31

2023

December 31

2022

$

$

Assets

Current

Cash and cash equivalents

34,706

42,691

Accounts receivable

33,437

32,872

Inventories

105,850

86,254

Income tax receivable

1,672

5,488

Derivative financial assets

591

Other current assets

5,707

19,857

Total current assets

181,963

187,162

Property, plant and equipment

84,600

77,951

Right-of-use assets

29,290

30,082

Intangible assets

29,304

31,563

Goodwill

11,825

11,825

Deferred tax assets

8,261

6,002

Other assets

4,959

3,400

Total non-current assets

168,239

160,823

Total assets

350,202

347,985

Liabilities

Current

Trade and accrued liabilities

37,024

40,200

Income tax payable

4,535

8,780

Current portion of deferred revenue

13,437

11,730

Current portion of lease liabilities

1,811

2,136

Current portion of long-term debt

25,000

Total current liabilities

81,807

62,846

Long-term debt

83,500

121,000

Deferred tax liabilities

5,284

6,959

Employee benefit plan obligations

13,393

11,643

Lease liabilities

28,328

28,266

Deferred revenue

5,629

2,354

Other liabilities

3,669

2,141

Total non-current liabilities

139,803

172,363

Total liabilities

221,610

235,209

Equity

128,592

112,776

Total liabilities and equity

350,202

347,985

Non‐IFRS Measures

EBITDA means net earnings (loss) before interest expenses, income tax (recovery) expense, depreciation and amortization. 5N+ uses EBITDA because it believes it is a meaningful measure of the operating performance of its ongoing business, without the effects of certain expenses. The definition of this non-IFRS measure used by the Company may differ from that used by other companies.

EBITDA is reconciled to the most comparable IFRS measure:

(in thousands of U.S. dollars)

Q4 2023

Q4 2022

FY 2023

FY 2022

$

$

$

$

Net earnings (loss)

2,284

(8,146)

15,399

(22,999)

Interest on long-term debt, imputed interest and other interest expense

2,129

716

8,834

5,192

Income tax (recovery) expense

(734)

(292)

3,275

4,711

Depreciation and amortization

4,057

4,051

16,110

17,732

EBITDA

7,736

(3,671)

43,618

4,636

Adjusted EBITDA means operating earnings (loss) as defined before the effect of impairment of inventories, share-based compensation expense (recovery), litigation and restructuring costs (income), impairment of non-current assets, loss on disposal of property, plant and equipment, loss on divestiture of subsidiary, loss on disposal of assets held for sale, and depreciation and amortization. 5N+ uses Adjusted EBITDA because it believes it is a meaningful measure of the operating performance of its ongoing business without the effects of certain expenses. The definition of this non-IFRS measure used by the Company may differ from that used by other companies.

Adjusted EBITDA margin is defined as Adjusted EBITDA divided by revenues.

Adjusted EBITDA is reconciled to the most comparable IFRS measure:

(in thousands of U.S. dollars)

Q4 2023

Q4 2022

FY 2023

FY 2022

$

$

$

$

Revenues

65,063

61,042

242,371

264,223

Operating expenses

(61,023)

(69,261)

(214,999)

(277,277)

Operating earnings (loss)

4,040

(8,219)

27,372

(13,054)

Share-based compensation expense (recovery)

414

(171)

1,432

999

Litigation and restructuring costs (income)

458

3,210

(8,314)

3,823

Impairment of non-current assets

64

672

12,478

Loss on disposal of property, plant and equipment

1,051

Loss on divestiture of subsidiary

7,834

7,834

Loss on disposal of assets held for sale

216

Depreciation and amortization

4,057

4,051

16,110

17,732

Adjusted EBITDA

9,033

6,705

38,323

30,028

Adjusted gross margin is a measure used to monitor the sales contribution after paying cost of sales, excluding depreciation and inventory impairment charges. 5N+ also expressed this measure in percentage of revenues by dividing the gross margin value by the total revenue.

Adjusted gross margin is reconciled to the most comparable IFRS measure:

(in thousands of U.S. dollars)

Q4 2023

Q4 2022

FY 2023

FY 2022

$

$

$

$

Total revenue

65,063

61,042

242,371

264,223

Cost of sales

(49,677)

(47,909)

(184,833)

(215,715)

Gross margin

15,386

13,133

57,538

48,508

Depreciation included in cost of sales

3,189

3,155

12,656

14,208

Adjusted gross margin

18,575

16,288

70,194

62,716

Adjusted gross margin percentage

28.5 %

26.7 %

29.0 %

23.7 %

Backlog represents the expected orders the Company has received, but has not yet executed, and that are expected to translate into sales within the next twelve months, expressed in dollars and estimated in number of days not to exceed 365 days. Bookings represent orders received during the period considered, expressed in number of days, and calculated by adding revenues to the increase or decrease in backlog for the period considered, divided by annualized year revenues. 5N+ uses backlog to provide an indication of expected future revenues in days, and bookings to determine its ability to sustain and increase its revenues.

Net debt is calculated as total debt less cash and cash equivalents. Any introduced IFRS 16 reporting measures in reference to lease liabilities are excluded from the calculation. 5N+ uses this measure as an indicator of its overall financial position.

The net debt to EBITDA ratio is defined as net debt divided by EBITDA.

Total debt and Net debt are reconciled to the most comparable IFRS measure:

(in thousands of U.S. dollars)

As at December 31, 2023

As at December 31, 2022

$

$

Bank indebtedness

Long-term debt including current portion

108,500

121,000

Lease liabilities including current portion

30,139

30,402

Subtotal Debt

138,639

151,402

Lease liabilities including current portion

(30,139)

(30,402)

Total Debt

108,500

121,000

Cash and cash equivalents

(34,706)

(42,691)

Net Debt

73,794

78,309

SOURCE 5N Plus Inc.

Continue Reading

Technology

Stowers Institute partners with Google DeepMind and leading research institutions to help reveal the regulatory language of the human genome

Published

on

By

Researchers provided biological expertise and feedback that helped guide the development of a new AI-powered resource released today. For the first time, scientists can explore a comprehensive map of more than 9 billion possible single-letter DNA changes through a web browser, helping them more quickly prioritize and interpret variants that may influence biology and disease and lay groundwork for future treatments. 

KEY HIGHLIGHTS 

Developed over several years, AlphaGenome Atlas is a one-petabyte dataset containing molecular-effect predictions for more than 9 billion possible single-letter DNA changes across the human genome.Until now, researchers lacked a single resource that could both rank variants across the genome and reveal the biological processes they are predicted to disrupt, a combination that could accelerate foundational discoveries, disease research and the search for therapeutic targets.Researchers from Google DeepMind, the Stowers Institute for Medical Research, Broad Institute, the University of Exeter, Memorial Sloan Kettering Cancer Center and Stanford University contributed scientific input and explored applications of the resource.

KANSAS CITY, Mo., Sept. 8, 2026 /PRNewswire/ — The human genome contains approximately 3 billion DNA letters, creating more than 9 billion possible single-letter changes. Testing the effects of each change in a laboratory would be practically impossible. Google DeepMind’s new AlphaGenome Atlas, available beginning today, gives scientists a comprehensive, searchable resource designed to accelerate understanding of the human genome.

The one-petabyte resource contains artificial intelligence-generated predictions for the molecular effects of more than 9 billion possible changes, creating what Google DeepMind describes as the most comprehensive catalogue of its kind.

Stowers Institute for Medical Research Investigator Julia Zeitlinger, Ph.D., partnered with the Google DeepMind team led by Vice President of Science and Chief Scientist Žiga Avsec, Ph.D., to map and interpret the patterns in DNA that regulate biological processes inside cells. At the same time, additional scientific collaborators from leading institutions across the United States and England helped test how the new resource could be used to identify impactful genetic variation in humans. The work is now available as a preprint on bioRxV. 

Zeitlinger has made significant contributions to the field of gene regulation and computational biology. In 2019, in an international collaboration that included Avsec, Zeitlinger and her team at the Stowers Institute developed a powerful AI framework, BPNet. This framework is now widely used to extract and dissect the DNA sequences that explain genome-wide biological data. Just last month, her lab unveiled a new AI method, PISA, which generates high-resolution visualizations of what AI models have learned from DNA. 

Stowers Institute Bioinformatics Scientist and Zeitlinger Lab member, Melanie Weilert, served as a lead author on the AlphaGenome project. With her deep expertise in interpretating AI models, she helped build the AlphaGenome Atlas resource to ask one of biology’s biggest questions: How does a cell know which genes to turn on and off?

“This is a very difficult problem because every cell type speaks a slightly different language, making it hard to know which rules are general,” Zeitlinger said. “With AlphaGenome, we can quickly query many cell types and look for general patterns by which genes are activated and repressed.”

Google DeepMind developed the technology behind the Atlas. Zeitlinger, who also leads the Stowers Institute’s AI Initiative, helped connect its predictions to the biological processes that give cells their identities and allow them to function.

“AlphaGenome Atlas is a powerful example of how AI can expand human knowledge and advance scientific discovery,” said VP Science, Google DeepMind and Chief Scientist, Google Cloud, Pushmeet Kohli, Ph.D. “By making this resource widely available, we hope scientists around the world can use it to better understand the language of life and what happens when individual letters in the human genome change.”

Scientists can access the resource through a web browser without writing code, allowing more researchers to explore genetic variation at a scale that was not previously possible.

“AlphaGenome Atlas is foundational research with the potential to have an impact across multiple areas of biology,” said Avsec. “We worked with experts in the field, including Julia, whose biological insight helped us explore how the resource can map functional elements in the genome and reveal their roles at the molecular level.” 

How Stowers scientists helped reveal the regulatory “words” of the genome

Every cell in the human body contains essentially the same DNA, yet different cells use that information in very different ways. Short DNA sequences called motifs act as regulatory instructions, helping control which genes are active, when they are activated and how strongly they operate.

Zeitlinger and her team used AlphaGenome Atlas to analyze regulatory motifs across the genome and determine what they reveal about the proteins, called transcription factors, that control gene activity. The researchers categorized these regulatory signals by function, distinguishing transcription factors that change whether DNA is accessible from those that also activate or repress genes.

Conducting this type of analysis experimentally across thousands of sites and many different cell types would require enormous time and resources. By making genome-wide predictions available in one searchable resource, the Atlas allowed Zeitlinger’s team to identify broader patterns in how genes are regulated and begin defining the general rules underlying the regulatory language of DNA.

“Having these motifs mapped at base-pair resolution across the genome and in many cell types gives us a searchable dictionary for non-coding DNA,” Zeitlinger said. “By giving the scientific community access to these predictions, AlphaGenome Atlas can accelerate how we identify potentially disease-causing variants while helping us understand the fundamental rules by which genes are regulated.”

“This collaboration demonstrates how Stowers scientists are helping shape emerging technologies, not simply adopting them,” said Stowers Institute President and Chief Scientific Officer Alejandro Sánchez Alvarado, Ph.D. “By pairing deep biological knowledge with the capabilities of AI, researchers can ask questions at a scale that was not previously possible and create new opportunities to more clearly understand human health and disease.”

The Atlas does not replace laboratory research. Instead, it can help scientists determine which variants and biological mechanisms should be investigated first, focusing experimental time and resources on the most promising questions.

“Tools such as AlphaGenome Atlas become most valuable when their predictions can be connected to meaningful biological questions,” said Stowers Institute Scientific Director Kausik Si, Ph.D. “Julia’s work brings together deep expertise in gene regulation and computational biology to help move us from simply reading DNA sequence toward understanding the rules that control gene activity.”

From billions of variants to focused biological questions 

AlphaGenome Atlas contains thousands of molecular-effect predictions for each variant across hundreds of human cell types and tissues. These predictions contribute to the new AlphaGenome Variant Impact, or AVI, score. They also enabled researchers to identify and map recurring DNA motifs, short sequences where transcription factors bind to help control gene activity.

The AVI score brings together predictions from AlphaGenome, AlphaMissense and evolutionary conservation data. It gives researchers a single measure for ranking variants by their potential impact across protein-coding and non-coding regions of the genome. Researchers can then examine which molecular processes, including gene expression, RNA splicing and protein function, are predicted to be affected.

The collaborating institutions explored how the resource could support several areas of human genetic research. Scientists at the Broad Institute used the AVI score to prioritize a previously overlooked non-coding variant associated with an unsolved rare disease case. At the University of Exeter, researchers applied Atlas to genomic data from more than 54,000 UK Biobank participants, uncovering additional associations between rare noncoding variants and protein levels. 

Watch a video from Google DeepMind and read a blog post announcing AlphaGenome Atlas.

Learn more and watch a tutorial of AlphaGenome Atlas 

AlphaGenome Atlas is available for non-commercial use through Google DeepMind’s website at deepmind.google.com/science/alphagenome/atlas. Its predictions are intended to support research and have not been validated or approved for clinical use.

About the Stowers Institute for Medical Research 

Founded in 1994 through the generosity of Jim Stowers, founder of American Century Investments, and his wife, Virginia, the Stowers Institute for Medical Research is a nonprofit, biomedical research organization with a focus on foundational research. Its mission is to expand our understanding of the secrets of life and improve life’s quality through innovative approaches to the causes, treatment, and prevention of diseases.

The Institute consists of 24 independent research programs. Of the approximately 500 members, over 370 are scientific staff that include principal investigators, fellows, technology center directors, postdoctoral scientists, graduate students, and technical support staff. Learn more about the Institute at stowers.org and about its graduate program at stowers.org/gradschool. 

Read an online version of the release here. 

Media contact 

Joe Chiodo 
Director of Communications 
Stowers Institute for Medical Research 
724-462-8529 
chiodo.joe@stowers.org 

View original content to download multimedia:https://www.prnewswire.com/news-releases/stowers-institute-partners-with-google-deepmind-and-leading-research-institutions-to-help-reveal-the-regulatory-language-of-the-human-genome-302872938.html

SOURCE Stowers Institute for Medical Research

Continue Reading

Technology

The Inner Circle acknowledges Daniel Beer as a Pinnacle Professional Member Inner Circle of Excellence

Published

on

By

NEW YORK, Sept. 8, 2026 /PRNewswire/ — Prominently featured in The Inner Circle, Daniel Beer is acknowledged as a Pinnacle Professional Member Inner Circle of Excellence for his contributions to Information Technology and Artificial Intelligence.

Daniel Beer has built a distinguished career as a technology executive, entrepreneur, and innovator dedicated to helping organizations harness technology to achieve sustainable growth and meaningful collaboration. As founder and chief executive officer of Trusted Associates and chief executive officer of Freeman and Clarke Inc., he leads initiatives that combine strategic technology leadership with emerging innovations in artificial intelligence and digital transformation.

Mr. Beer specializes in information technology strategy, platform development, organizational modernization, digital infrastructure, and fractional chief information officer and chief technology officer services. Through Freeman and Clarke Inc., he provides executive technology leadership that enables organizations to align technology investments with long term business objectives. At Trusted Associates, he focuses on developing collaborative technology platforms, cultivating strategic partnerships, creating innovative applications, and making investments in artificial intelligence companies that advance practical, real world solutions.

Mr. Beer earned a Bachelor of Music Education from the University of Sydney in 1997 before completing an equivalency certification for a Bachelor of Applied Science in Computer Science through the University of Maryland in 2012. His unique educational background combines creativity with technical expertise, allowing him to approach technology challenges with both analytical precision and innovative thinking.

Throughout his career, Mr. Beer has consistently demonstrated visionary leadership. He founded Techknowledgy Group at the age of 20 and successfully grew the company into a respected managed services provider over a fifteen year period. Later, as Chief Information Officer for the New York Hotel Trades Council, he led the modernization of the organization’s information systems and digital infrastructure, significantly improving operational efficiency and technology capabilities. Today, he continues expanding his influence through leadership roles with Trusted Associates, Freeman and Clarke Inc., and as an investor and advisory board member for Relate Research and Technology Company.

His professional accomplishments have earned recognition through inclusion in Marquis Who’s Who Top Executives, honoring his leadership, innovation, and contributions to the field of information technology.

Outside of his professional endeavors, Mr. Beer enjoys singing in church choirs, supporting personal development programs, and participating in animal rescue efforts, including fostering and rescuing dogs alongside his family. He credits the mentors who invested in his growth without expecting anything in return for shaping both his leadership philosophy and his commitment to serving others.

Looking ahead, Mr. Beer plans to continue advancing technology solutions that promote global collaboration while pursuing initiatives that improve literacy, raise awareness of neurodiversity, reduce incarceration rates, and create opportunities that benefit society as a whole. He remains committed to using innovation as a force for positive change.

Guided by his W5 philosophy, Mr. Beer believes true success is measured by helping others succeed. Through collaboration, communication, service, and innovation, he continues to build organizations and technologies that create lasting value for clients, communities, and future generations.

Contact: Katherine Green, 516-825-5634, editorialteam@continentalwhoswho.com

View original content:https://www.prnewswire.com/news-releases/the-inner-circle-acknowledges-daniel-beer-as-a-pinnacle-professional-member-inner-circle-of-excellence-302872896.html

SOURCE The Inner Circle

Continue Reading

Technology

Thoma Bravo Announces Strategic Growth Investment in Tanda

Published

on

By

Investment to accelerate Tanda’s product innovation and global growth

BRISBANE, Australia and SAN FRANCISCO, Sept. 8, 2026 /PRNewswire/ — Thoma Bravo, the world’s largest software-focused investment firm, today announced a strategic growth investment in Tanda, a leading workforce management, payroll and HR platform for shift-based workers. Thoma Bravo’s investment will support Tanda’s continued product innovation, including the company’s AI roadmap and its expansion into new markets. Tanda’s co-founders will remain significant shareholders and will continue to lead the company, with Jake Phillpot remaining Chief Executive Officer. Terms of the transaction were not disclosed.

Tanda is the market leader in workforce management for shift-based employers, serving approximately 8,000 businesses globally across hospitality, retail, quick-service restaurants, healthcare and other frontline industries. Tanda’s integrated workforce management platform combines employee recruiting, onboarding, rostering, time and attendance, gross wage calculations and payroll on a single codebase. This natively built product suite enables employers in complex, highly regulated markets to manage compliance and ensure employees are paid accurately. Trusted by thousands of organizations, Tanda’s platform powers the daily operations of some of the most demanding frontline businesses in the world.

“Taking on an investor was a very big decision for Tanda,” said Jake Phillpot, Co-Founder & Chief Executive Officer of Tanda. “We’ve been a bootstrapped company with no outside capital since we were founded 14 years ago. What started as an idea when we were still housemates at university has become a global business that we have built without taking shortcuts. Through a lot of hard work, we have market-leading products, growing market share and so much more room to grow. We thought the time was right to take on our first investor.”

“Thoma Bravo was the obvious choice as our financial partner,” Phillpot continued. “They understand software at an extraordinary level, have spent decades helping companies like ours scale and share our ambition for what Tanda can become. By partnering with the world’s number one software investor, we intend to become the global category leader in our space. Most importantly, the things that make Tanda precious won’t change. The founders will still come to work every day, and we’ll still obsess over how we can make our products better for our customers.”

“Managing and compensating employees accurately is a fundamental obligation of all employers, yet it remains a universal challenge, particularly for businesses with shift-based employees,” said Carl Press, a Partner at Thoma Bravo. “Employers are frustrated by a patchwork of legacy systems that cannot address their complex needs and expose them to operational and legal risks. Jake and his co-founders identified this problem and built Tanda from the ground up with customers and their employees at the center of every product decision. In doing so, they’ve laid the groundwork to become the definitive AI-native workforce management solution in the shift-based economy. We couldn’t be more thrilled to help them drive the next chapter of accelerated growth and innovation.”

“Tanda has everything we look for in an investment: market leadership, a fiercely loyal customer base and a product-first founding team with deep domain expertise,” said Adam Kinalski, a Principal at Thoma Bravo. “Jake and his co-founders have built a rare business that matches strong product-market fit with exceptional operational execution. We’re excited to partner with them on their mission to make Tanda the global standard in workforce management and payroll software for shift-based employers.”

Barrenjoey Advisory Pty Ltd is serving as financial advisor to Tanda, and SBA Law is serving as legal counsel. Piper Sandler & Co. is serving as exclusive financial advisor to Thoma Bravo, and Kirkland & Ellis LLP and Allens are serving as legal counsel.

About Thoma Bravo
Thoma Bravo is the world’s largest software-focused investment firm, with approximately $170 billion in assets under management as of June 30, 2026. Partnering with some of the world’s most sophisticated investors, Thoma Bravo’s private equity and private credit platforms reflect a focused investment strategy, supported by disciplined execution, deep sector expertise and leadership continuity. Over the past 20-plus years, Thoma Bravo has acquired or invested in approximately 600 software and technology companies, representing more than $325 billion of aggregate enterprise value (including control and non-control investments, as well as add-on acquisitions). Learn more at thomabravo.com and on LinkedIn.

About Tanda
Founded in 2012 and headquartered in Brisbane, Australia, Tanda (operating internationally as Workforce.com) is an all-in-one payroll, HR and workforce management system for businesses with shift-based and hourly workforces. Tanda’s platform brings rostering, time and attendance, award interpretation, compliance, payroll and HR onboarding together in a single system, helping employers in hospitality, retail, healthcare and other frontline industries schedule efficiently and pay employees accurately. The company serves thousands of customers across Australia, North America, the United Kingdom and Southeast Asia. For more information, visit tanda.co.

For Thoma Bravo

Abby Farr
Vice President, Communications & Marketing
+1 646-957-2067
afarr@thomabravo.com    

For Tanda

Georgie Pollok
Head of Marketing
media@tanda.com.au 

View original content to download multimedia:https://www.prnewswire.com/news-releases/thoma-bravo-announces-strategic-growth-investment-in-tanda-302872908.html

SOURCE Thoma Bravo

Continue Reading

Trending